Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avatrombopag - Swedish Orphan Biovitrum

Next Previous
Drug Profile

Avatrombopag - Swedish Orphan Biovitrum

Alternative Names: AKR-501; AKR-501 monomaleate; Avatrombopag maleate; DOPTELET; DOPTELET Sprinkle; E-5501; Su Ke Xin; YM-477

Latest Information Update: 01 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer Dova Pharmaceuticals; Eisai Co Ltd; Shanghai Fosun Pharmaceutical; Swedish Orphan Biovitrum
  • Class Antithrombotics; Piperazines; Piperidines; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic thrombocytopenic purpura; Thrombocytopenia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Idiopathic thrombocytopenic purpura; Thrombocytopenia

Most Recent Events

  • 31 Jul 2026 Swedish Orphan Biovitrum plans a phase II/III trial for Aplastic anaemia (Second-line therapy or greater) (PO) (NCT07786922)
  • 29 Oct 2025 Swedish Orphan Biovitrum completes phase-III clinical trials in Idiopathic thrombocytopenic purpura in Japan (PO) (NCT05369208)
  • 28 Oct 2025 Swedish Orphan Biovitrum completes phase III clinical trials in Thrombocytopenia (In adolescents, In children, In infants) in USA, France, Hungary, Germany, Poland, Russia, United Kingdom, Ukraine, Turkey (PO) (NCT04516967)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top